Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural development of biological response modifiers based on retinoids and thalidomide.

Yuichi Hashimoto1

  • 1Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-0032, Japan. hashimot@iam.u-tokyo.ac.jp

Mini Reviews in Medicinal Chemistry
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phthalimide: a potential warhead for switchable and bioorthogonal conjugation.

Chemical communications (Cambridge, England)·2025
Same author

Photo-Enhanced Aqueous Solubilization of Azobenzene-Incorporated Lipids.

Chemical & pharmaceutical bulletin·2025
Same author

Development of subtype-selective estrogen receptor modulators using the bis(4-hydroxyphenyl)silanol core as a stable isostere of bis(4-hydroxyphenyl)methanol.

RSC advances·2023
Same author

Distribution of Retinoids Applied Exogenously to Chick Limb Buds: an Autoradiographic Analysis: (Retinoic Acid/Limb Bud/Pattern Formation/Autoradiograph).

Development, growth & differentiation·2023
Same author

Design, synthesis and structure-activity relationship of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxyisoprop-2-yl)phenylsilane derivatives as liver X receptor agonists.

Bioorganic & medicinal chemistry·2022
Same author

Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties.

ACS medicinal chemistry letters·2022

Biological response modifiers (BRMs) like retinoids and thalidomide offer new therapeutic avenues for chronic diseases. Medicinal chemistry efforts are yielding targeted compounds for gene expression and multi-target modulation.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • The advent of antibiotics shifted disease patterns from acute infectious to chronic non-infectious conditions.
  • Biological response modifiers (BRMs) are emerging as crucial therapeutic agents, acting beyond selective toxicity.
  • Retinoids and thalidomide represent key classes of BRMs with distinct mechanisms of action.

Purpose of the Study:

  • To explore the medicinal chemical and structural development of retinoids and thalidomide derivatives.
  • To identify and synthesize novel compounds targeting nuclear receptors and multi-target pathways.
  • To develop advanced therapeutic agents for chronic and complex diseases.

Main Methods:

  • Computer-assisted molecular design for retinoid analogs.

Related Experiment Videos

  • Structural modification of thalidomide to target specific molecular pathways.
  • Synthesis and evaluation of novel agonists, antagonists, and synergists for RARs and RXRs.
  • Investigation of thalidomide's multi-target interactions, including TNF-alpha and nuclear receptors.

    • Main Results:

    • Development of class/subtype-selective agonists, synergists, and antagonists for RARs and RXRs.
    • Identification of thalidomide as a multi-target drug with potential interactions with TNF-alpha, nuclear androgen receptor, aminopeptidases, and alpha-glucosidase.
    • Synthesis of potent thalidomide derivatives with potential for novel immunomodulatory, anti-angiogenic, and anti-tumor activities.

    Conclusions:

    • Medicinal chemistry-driven development of BRMs offers promising strategies for treating chronic diseases.
    • Targeted retinoid and thalidomide analogs show potential as next-generation therapeutics.
    • Further research into these compounds could lead to novel treatments for cancer and inflammatory conditions.